4 years ago

Rationale and design of the DEAR-OLD trial: randomized evaluation of routinely Deferred versus EARly invasive strategy in elderly patients of 75years or OLDer with non-ST-elevation myocardial infarction

Comparing with conservative strategy, early invasive approach has been shown to be beneficial for initially stabilized patients with non-ST-elevation myocardial infarction (NSTEMI). However, concerns of increased risk of bleeding and other complications associated with early revascularization in patients aged ≥75years persist. A routinely deferred invasive strategy aiming to facilitate revascularization after stabilizing the culprit lesion predominate across China. Aim To compare efficacy and safety of deferred invasive strategy versus guideline-recommended early invasive strategy in initially stabilized Chinese patients aged ≥75years with NSTEMI. Methods Twenty qualified centers from ten different provinces throughout mainland China will contribute to the study. Eligible patients will be central randomized to a routine deferred invasive approach or an early invasive approach (coronary angiography >72hours or <24hours of admission and appropriate revascularization). Patients meeting the inclusion criteria but not randomized for any reason will be registered. The primary endpoint of the present study is a composite of all-cause mortality, non-lethal (re) MI, ischemic stroke and urgent revascularization at one year. Non-inferiority design is used and the inferiority margin was set to be 5%. The goal is to enroll 696 patients with expected primary endpoint rates of 30%, two-tailed α of 0.05, power of 80%, and drop-out rate of 5%. Conclusions the DEAR-OLD trial is a prospective, nationwide, multi-center, non-inferiority designed, open-label randomized clinical trial evaluating efficacy and safety of routinely deferred invasive strategy compared with early invasive strategy in Chinese elderly patients with NSTEMI.

Publisher URL: www.sciencedirect.com/science

DOI: S0002870317303526

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.